Immediate Impact

23 standout
Sub-graph 1 of 10

Citing Papers

Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
2024 Standout
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
2024 Standout
1 intermediate paper

Works of Jesús Alarcón being referenced

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
2021
Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma
2007
and 1 more

Author Peers

Author Last Decade Papers Cites
Jesús Alarcón 50 100 19 115 56 12 188
Dörte Wren 67 48 12 44 29 16 182
Christina Parsons 34 71 17 92 12 13 208
A. Alietti 15 74 4 137 45 9 225
Rachel Wei 41 166 5 138 124 17 259
Adi Broyde 21 61 2 89 33 8 156
Kar Fai Chow 11 37 5 79 50 18 155
Sabine Oeschger 25 68 2 139 64 9 241
Elías Gracia 71 153 2 125 27 14 283
Natalia Castrejón de Anta 13 107 2 77 33 17 192
Catherine Vézina 43 153 4 38 30 11 274

All Works

Loading papers...

Rankless by CCL
2026